Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timo Joensuu

Showing results (31-40 of 67) with videos related to

Pageof 7
Sort By:
Human Gene Therapy|October 9, 2013
[(18)F]-fluorodeoxyglucose positron emission tomography and computed tomography in response evaluation of oncolytic adenovirus treatments of patients with advanced cancerAnniina Koski, Helena Ahtinen, Heidi Liljenback, et al.
International Journal of Radiation Oncology, Biology, Physics|December 17, 2009
A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancerGreetta Joensuu, Timo Joensuu, Petri Nokisalmi, et al.
Oncotarget|February 22, 2018
Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patientsKristian Taipale, Siri Tähtinen, Riikka Havunen, et al.
European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|October 6, 2006
Oral tongue carcinoma and its treatment in FinlandAntti A Mäkitie, Petri Koivunen, Harri Keski-Säntti, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 5, 2016
Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic ImmunotherapyKristian Taipale, Ilkka Liikanen, Anniina Koski, et al.
Oncoimmunology|April 9, 2016
Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancerSimona Bramante, Anniina Koski, Ilkka Liikanen, et al.
Journal for Immunotherapy of Cancer|February 23, 2022
Oncolytic adenovirus decreases the proportion of TIM-3<sup>+</sup> subset of tumor-infiltrating CD8<sup>+</sup> T cells with correlation to improved survival in patients with cancerIlkka Liikanen, Saru Basnet, Dafne C A Quixabeira, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 2, 2011
Sodium iodide symporter SPECT imaging of a patient treated with oncolytic adenovirus Ad5/3-Δ24-hNISMaria Rajecki, Aki Kangasmäki, Leena Laasonen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 9, 2012
Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancerOtto Hemminki, Iulia Diaconu, Vincenzo Cerullo, et al.
Oncotarget|May 10, 2019
<sup>177</sup>Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancerFinn Edler von Eyben, Aviral Singh, Jingjing Zhang, et al.
Pageof 7

Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
Human Gene Therapy|October 9, 2013
[(18)F]-fluorodeoxyglucose positron emission tomography and computed tomography in response evaluation of oncolytic adenovirus treatments of patients with advanced cancerAnniina Koski, Helena Ahtinen, Heidi Liljenback, et al.
International Journal of Radiation Oncology, Biology, Physics|December 17, 2009
A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancerGreetta Joensuu, Timo Joensuu, Petri Nokisalmi, et al.
Oncotarget|February 22, 2018
Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patientsKristian Taipale, Siri Tähtinen, Riikka Havunen, et al.
European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|October 6, 2006
Oral tongue carcinoma and its treatment in FinlandAntti A Mäkitie, Petri Koivunen, Harri Keski-Säntti, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 5, 2016
Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic ImmunotherapyKristian Taipale, Ilkka Liikanen, Anniina Koski, et al.
Oncoimmunology|April 9, 2016
Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancerSimona Bramante, Anniina Koski, Ilkka Liikanen, et al.
Journal for Immunotherapy of Cancer|February 23, 2022
Oncolytic adenovirus decreases the proportion of TIM-3<sup>+</sup> subset of tumor-infiltrating CD8<sup>+</sup> T cells with correlation to improved survival in patients with cancerIlkka Liikanen, Saru Basnet, Dafne C A Quixabeira, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 2, 2011
Sodium iodide symporter SPECT imaging of a patient treated with oncolytic adenovirus Ad5/3-Δ24-hNISMaria Rajecki, Aki Kangasmäki, Leena Laasonen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 9, 2012
Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancerOtto Hemminki, Iulia Diaconu, Vincenzo Cerullo, et al.
Oncotarget|May 10, 2019
<sup>177</sup>Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancerFinn Edler von Eyben, Aviral Singh, Jingjing Zhang, et al.
Pageof 7